Zhejiang Dongri: Correction of some financial data such as revenue in the Q3 2025 report

Zhejiang Dongri announced that the company has corrected some erroneous information entered in the third quarter report for 2025. After the correction, the operating income for this reporting period is 185 million yuan, a year-on-year decrease of 3.87%; the total profit is 60.8994 million yuan, a year-on-year increase of 9.80%; the net profit attributable to shareholders of the listed company is 46.0602 million yuan, a year-on-year increase of 4.94%. There are no changes to the relevant data from the beginning of the year to the end of the reporting period

ZJDR: The net profit for the third quarter was 43.8912 million yuan, a year-on-year decrease of 4.71%

ZJDR announced that its revenue for the third quarter was 192 million yuan, a year-on-year increase of 4.03%; net profit was 43.8912 million yuan, a year-on-year decrease of 4.71%. Revenue for the first three quarters was 558 million yuan, a year-on-year increase of 2.66%; net profit was 115 million yuan, a year-on-year increase of 9.13%

Zhejiang Dongri released its semi-annual performance, with a net profit attributable to the parent company of 68.83 million yuan, a year-on-year increase of 12.12%

According to the Zhitong Finance APP, ZJDR disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 373 million yuan, a year-on-year increase of 6.23%; net profit attributable to the parent company was 68.83 million yuan, a year-on-year increase of 12.12%; net profit excluding non-recurring items was 66.37 million yuan, a year-on-year increase of 10.63%; basic earnings per share were 0.16 yuan

ZJDR: Does not involve "brain-computer interface" business

According to the Zhitong Finance APP, ZJDR announced a stock price fluctuation stating that the company's main business is the operation and management of wholesale trading markets for agricultural and sideline products (including market trading management and market leasing business), fresh food delivery services, and related businesses in the production and processing of bean products, and does not involve "brain-computer interface" business

The A-share brain engineering concept saw a short-term surge, with Innovative Medical hitting the daily limit, and Thalys, Rongtai Health, ZJDR, CASIT, Sanbo Neuroscience, and Haojiang Intelligent following suit